Novel anellovector compositions and methods

JP2024539621A5Pending Publication Date: 2025-10-22FLAGSHIP PIONEERING INNOVATIONS V INC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
JP2024522072
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2022-03-16
Filing Date
2022-10-11
Publication Date
2025-10-22

AI Technical Summary

Technical Problem

There is a need for suitable vectors to deliver therapeutic genetic material to patients effectively while minimizing immune and inflammatory responses.

Method used

The use of Anelloviridae vectors, such as synthetic Anellovectors, which are engineered to encapsulate genetic elements within a proteinaceous exterior, allowing for targeted delivery to eukaryotic cells with reduced immunogenicity and controlled integration frequency, using modified Anellovirus capsid proteins like CAV VP1 to confer therapeutic effects.

Benefits of technology

Anelloviridae vectors provide efficient delivery of genetic material to eukaryotic cells with minimal immune response, achieving therapeutic outcomes by modulating cellular functions and treating diseases with reduced integration frequency and immunogenicity.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 00000279_0000
    Figure 00000279_0000
  • Figure 00000279_0001
    Figure 00000279_0001
  • Figure 00000279_0002
    Figure 00000279_0002
Patent Text Reader

Abstract

The present invention relates generally to compositions for making and administering Anelloviridae vectors (e.g., anellovectors) and uses thereof.
Need to check novelty before this filing date? Find Prior Art